Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
| Autor: | Viviana Loddo, Giuseppe Console, Antonio Maria Rossetti, Massimo Martino, Barbara Loteta, Tiziana Gangemi, Filippo Antonio Canale, Gaetana Porto, Annalisa Paviglianiti, Nicola Meliambro, Anna Ferreri, Marta Pugliese, Letteria Russo, Pasquale Fabio Provenzano, Tiziana Moscato, Domenico Porcino, Antonella Di Costanzo, Virginia Naso, Valentina Romeo, Giuseppe Irrera, Giuseppa Cusumano, Salvatore Gallo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Melphalan
Quinuclidines Pyridines Vomiting Nausea medicine.drug_class medicine.medical_treatment Transplantation Autologous Dexamethasone chemistry.chemical_compound Autologous stem-cell transplantation Multiple myeloma medicine Humans Netupitant Antiemetic ASCT Chemotherapy business.industry Palonosetron Hematopoietic Stem Cell Transplantation Netupitant/palonosetron (NEPA) Oncology chemistry High-dose melphalan Anesthesia Quality of Life Chemotherapy-induced nausea and vomiting (CINV) Antiemetics Original Article medicine.symptom business medicine.drug |
| Zdroj: | Supportive Care in Cancer |
| ISSN: | 1433-7339 0941-4355 |
| Popis: | Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent adverse events compromising quality of life (QoL) in patients undergoing autologous stem cell transplantation (ASCT). However, CINV prophylaxis is still lacking uniformity for high-dose melphalan (HDM), which is used to condition patients with multiple myeloma (MM). Netupitant/palonosetron (NEPA) is administered with dexamethasone (DEXA) for CINV prevention in several chemotherapy regimens. Our study aims to assess the efficacy of NEPA, without DEXA, in preventing CINV in 106 adult patients with MM receiving HDM and ASCT. All patients had antiemetic prophylaxis with multiple doses of NEPA 1 h before the start of conditioning and after 72 h and 120 h. A complete response (CR) was observed in 99 (93%) patients at 120 h (overall phase). The percentage of patients with complete control was 93%. The CR rate during the acute phase was 94% (n = 100). During the delayed phase, the CR rate was 95% (n = 101). Grade 1 nausea and vomiting were experienced by 82% and 12% of the patients, respectively. Grade 2 nausea was reported in 18% and vomiting in 10% of patients. Our results showed, for the first time, that NEPA, without DEXA, was a well-tolerated and effective antiemetic option for MM patients receiving HDM followed by ASCT. Supplementary Information The online version contains supplementary material available at 10.1007/s00520-021-06472-7. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink